CoChat
Sign Up
Cited by 165Complementary and Alternative Medicine StudiesPharmacogenetics and Drug MetabolismPhytochemistry Medicinal Plant Applications

The DOI matches its Crossref record; 404 of the 404 references it cites were found in a registry or an index; none of the 342 sources its claims cite is checked for support yet.

Pharmacokinetic Herb-Drug Interactions (Part 2): Drug Interactions Involving Popular Botanical Dietary Supplements and Their Clinical Relevance

Open access
Gurley, Bill, Fifer, Espero, Gardner, Zoë·2012·Planta Medica
DOI 10.1055/s-0031-1298331
Open this paper in CoChat — free accountOpen PDF

Abstract

In Part 2 of this review, a critical examination of the pertinent scientific literature is undertaken in order to assess the interaction risk that popular dietary supplements may pose when taken concomitantly with conventional medications. Botanicals most likely to produce clinically important herb-drug interactions are those whose phytochemicals act as mechanism-based inhibitors of cytochrome P450 enzyme activity (e.g., Hydrastis canadensis, Piper nigrum, Schisandra chinensis ) or function as ligands for orphan nuclear receptors (e.g., Hypericum perforatum ). In addition, several external factors unrelated to phytochemical pharmacology can augment the drug interaction potential of botanical supplements. Key Words herb-drug interaction - plant secondary metabolites - cytochrome P450 enzymes - transferases - ATP-binding cassette transporters - solute carrier membrane transport proteins - botanical dietary supplements - black cohosh - Echinacea - garlic - Ginkgo biloba - ginseng - goldenseal - kava - black pepper - piperine - Schisandra - milk thistle - St. John's wort - methylenedioxyphenyl-containing compounds

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This review critically assesses clinical evidence for herb-drug interactions of popular botanical supplements, concluding most pose low risk at recommended doses while goldenseal, black pepper/piperine, Schisandra, and St. John’s wort pose high risk. Risk is driven mainly by mechanism-based CYP inhibition from methylenedioxyphenyl phytochemicals or nuclear receptor activation by hyperforin/PXR.

Key findings

  • Black cohosh, Echinacea, garlic, ginkgo at ≤240 mg/day, ginseng, kava, and milk thistle were rated low interaction risk; goldenseal, black pepper/piperine, Schisandra, and St. John’s wort were rated high risk.
  • Goldenseal: 14 days of supplementation (~209 mg isoquinoline alkaloids daily) significantly increased midazolam AUC, Cmax, and elimination half-life, with effects proportional to clarithromycin 1000 mg daily; hydrastine inhibited CYP3A4 with IC50 = 25 µM versus berberine IC50 = 400 µM.
  • Black pepper/piperine: every prospective human trial showed improved oral bioavailability, with mean AUC increases of phenytoin 16–133%, rifampicin 69%, propranolol 103%, theophylline 96%, and nevirapine 170%; concern is greatest with CYP3A and/or ABCB1 substrates and piperine/piperamides >10 mg.
  • St. John’s wort: hyperforin is a potent PXR activator with EC50 = 23 nM, below usual human plasma concentrations of ~100–300 nM; >70% of prescription medications are susceptible, and extracts with <1% hyperforin are less likely to produce clinically relevant interactions.
  • Schisandra: clinical AUC increases were 1.5-fold for talinolol, 2.1-fold for tacrolimus, and 2.0-fold for midazolam; gomisins B, C, and G inhibited human CYP3A4 with IC50 values <1.5 µM.
  • Ginkgo: among 29 prospective clinical trials, 23 observed no significant effects on drug disposition, 5 observed modest inhibition, and 3 showed evidence of CYP3A4, CYP2C9, or CYP2C19 induction; doses >240 mg/day may increase interaction prospects.
  • Garlic: garlic oil inhibited human CYP2E1 by almost 40% in young adults and 25% in elderly adults; garlic powder reduced saquinavir mean AUC, 8-hour trough concentrations, and Cmax by 50%; a standardized garlic extract increased duodenal ABCB1 expression by 31%.
  • Milk thistle: standard extracts had no observable effects on many drugs; silymarin increased talinolol AUC by 36% and reduced metronidazole AUC by 29%; in CYP2C9*1/*1 subjects, silymarin produced a 2-fold increase in losartan AUC and Cmax, but not in CYP2C9*1/*3 subjects.

Methods

  • Narrative critical review of published clinical and nonclinical literature on selected popular botanical dietary supplements, presented as Part 2 of a two-part review.
  • For each botanical, the paper assesses in vitro, animal, and human pharmacokinetic interaction data, focusing on cytochrome P450 enzymes, transferases, ABC transporters, and solute carrier transporters, and assigns a qualitative interaction risk rating.
  • No new primary data are reported; no systematic search strategy or meta-analysis is described.

Limitations

  • The paper states that phytochemical profiles and label claims for “standardized” botanical products can vary considerably, which can affect interpretation of efficacy and herb-drug interaction studies.
  • The paper states that most botanicals have not been evaluated clinically and that no clinical assessments of botanical extracts using novel bioavailability-enhancing formulations have been reported.
  • The paper notes methodological concerns in specific studies, such as the Yuan et al. ginseng-warfarin trial being underpowered, using inadequate sampling for AUC, and using a non-stereoselective assay; evident from the text, the review’s risk ratings are qualitative and not based on formal meta-analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1055/s-0031-1298331

Cites

404 of 404 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 342 cited sources checked · 0 supported · 0 flagged

Show all 156 claims

  • It may state two separate claims as one. 67
  • The quote only partly states this claim. 16
  • Probably not a substantial claim. 15
96 of 96

  • The paper relies on this without support.

    The products and doses used in the cited clinical studies are representative of commercially available botanical supplements when taken as recommended.

    “most commercially available garlic supplements pose only a limited risk”

  • The paper relies on this without support.

    Most St. John's wort extracts are currently standardized to contain 3% hyperforin.

    “Most SJW extracts are currently standardized to contain 3% hyperforin, yet many brands may possess amounts well below this value.”

  • The paper relies on this without support.

    Many brands of St. John's wort may contain hyperforin amounts well below 3%.

    “Most SJW extracts are currently standardized to contain 3% hyperforin, yet many brands may possess amounts well below this value.”

  • The paper relies on this without support.

    Few St. John's wort products are specifically labeled as having low hyperforin content.

    “Unfortunately for consumers, few SJW products are specifically labeled as having low hyperforin content.”

  • The paper relies on this without support.

    PXR is polymorphic, and certain mutations produce significant functional defects in CYP3A transcription.

    “Like many CYPs, PXR is polymorphic, and certain mutations produce significant functional defects in terms of CYP3A transcription.”

  • The paper relies on this without support.

    Poor dissolution characteristics are major obstacles to phytochemical bioavailability and efficacy.

    “Recognizing that poor dissolution characteristics represent major obstacles to phytochemical bioavailability and efficacy, several dietary supplement manufacturers have recently incorporated novel methods of formulating botanical extracts as a means of improving oral absorption [387,388].”

  • The paper relies on this without support.

    No clinical assessments of the herb-drug interaction potential of botanical extracts incorporating novel formulations have been reported to date.

    “To date, no clinical assessments of the herb-drug interaction potential of botanical extracts incorporating these novel formulations have been reported.”

  • The paper relies on this without support.

    The vast majority of botanical supplements have not been evaluated in a clinical setting.

    “Not surprisingly, the vast majority of these botanicals have yet to be evaluated in a clinical setting.”

  • The paper relies on this without support.

    Hyperforin is a principal mediator of St. John's wort's antidepressive action.

    “Hyperforin, a principal mediator of SJWʼs antidepressive action, lies at the heart of the herbʼs drug interaction potential.”
9 of 9

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Conflicting descriptions of typical ginkgo study doses

    Major

    The paper says the majority of clinical studies used 240 mg twice daily, or 480 mg/day, but later says most human studies used 240 mg/day or less.

1 of 1

Citations

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 54

  1. Borrelli F, Izzo AA, Ernst E. Pharmacological effects of Cimicifuga race- mosa. Life Sci 2003; 73: 1215-1229
  2. Huntley A, Ernst E. A systematic review of the safety of black cohosh. Menopause 2003; 10: 58-64
  3. Shams T, Setia MS, Hemmings R, McCusker J, Sewitch M, Ciampi A. Effi- cacy of black cohosh-containing preparations on menopausal symp- toms: a meta analysis. Altern Health Med 2010; 16: 36-44
  4. Viereck V, Emons G, Wuttke W. Black cohosh: just another phytoestro- gen? Trend Endocrinol Metab 2005; 16: 214-221
  5. Li JX, Yu ZY. Cimicifugae rhizoma: from origins, bioactive constituents to clinical outcomes. Curr Med Chem 2006; 13: 2927-2951
  6. van Breeman RB, Liang W, Banuvar S, Shulman LP, Pang Y, Tao Y, Nikolic D, Krock KM, Fabricant DS, Chen S-N, Hedayat S, Bolton JL, Pauli GF, Piersen CE, Krause EC, Geller SE, Farnsworth NR. Pharmacokinetics of 23-epi-26-deoxyactein in women after oral administration of a stan- dardized extract of black cohosh. Clin Pharmacol Ther 2010; 87: 219- 225
  7. Tsukamoto S, Aburatani M, Ohta T. Isolation of CYP3A4 inhibitors from the black cohosh (Cimicifuga racemosa). eCAM 2005; 2: 223-226
  8. Jiang B, Kronenberg F, Nuntanakorn P, Qiu M-H, Kennelly EJ. Evaluation of the botanical authenticity and phytochemical profile of black co- hosh products by high-performance liquid chromatography with se- lected ion monitoring liquid chromatography-mass spectrometry. J Agric Food Chem 2006; 54: 3242-3253 10
  9. Budzinski JW, Trudeau VL, Drouin CE, Panahi M, Arnason JT, Foster BC. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glyco- protein (P-gp) in Caco-2 cell monolayers by selected commercial- source milk thistle and goldenseal products. Can J Physiol Pharmacol 2007; 85: 966-978
  10. Hellum BH, Nilsen OG. In vitro inhibition of CYP3A4 metabolism and P- glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 2008; 102: 466-475
  11. Hansen TS, Nilsen OG. In vitro CYP3A4 metabolism: inhibition by Echi- nacea purpurea and choice of substrate for the evaluation of herbal in- hibition. Basic Clin Pharmacol Toxicol 2008; 103: 445-449
  12. Modarai M, Yang M, Suter A, Kortenkamp A, Heinrich M. Metabolomic profiling of liquid Echinacea medicinal products with in vitro inhibi- tory effects on cytochrome P450 3A4 (CYP3A4). Planta Med 2010; 76: 378-385
  13. Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterol- emia: a meta analysis of randomized clinical trials. Ann Intern Med 2000; 133: 420-429
  14. Payen L, Sparfel L, Courtois A, Vernhet L, Guillouzo A, Fardel O. The drug efflux pump MRP-2: regulation of expression in physiopathological situations by endogenous and exogenous compounds. Cell Biol Toxicol 2002; 18: 221-233
  15. Chan P-C, Xia Q, Fu PP. Ginkgo biloba leaves extract: biological, medici- nal, and toxicological effects. J Environ Sci Health C 2007; 25: 211-244 105
  16. Canter PH, Ernst E. Ginkgo biloba is not a smart drug: an updated sys- tematic review of randomized clinical trials testing the nootropic ef- fects of G. biloba extracts in healthy people. Hum Psychopharmacol 2007; 22: 265-278 107
  17. Numa AM, Abbott FS, Chang TKH. Effect of Ginkgo biloba extract on oxi- dative metaolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype. Can J Physiol Pharmacol 2007; 85: 848-855 118
  18. Tiong KH, Yiap BC, Tan EL, Ismail R, Ong CE. In vitro modulation of nat- urally occurring flavonoids on cytochrome P450 2A6 (CYP2A6) activ- ity. Xenobiotica 2010; 40: 458-466 123
  19. Smith M, Lin KM, Zheng YP. An open trial of nifedipine-herb interac- tions: nifedipine with St Johnʼs wort, ginseng, or Ginkgo biloba [Abstr.]. Clin Pharmacol Ther 2001; 69: P86 154
  20. Sun H, Zuo Z, Yin OQ, Tomlinson B, Chow MS. A high-throughput cock- tail method for screening the effect of herbal product on liver isozyme activities: experience with Ginkgo biloba. Clin Pharmacol Ther 2002; 71: P100 155
  21. Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. The ef- fects of Ginkgo biloba extracts on the pharmacokinetics and pharma- codynamics of donepezil. J Clin Pharmacol 2004; 44: 538-542 160
  22. Fan L, Mao X-Q, Tao GY, Wang G, Jiang F, Chen Y, Li Q, Zhang W, Lei H-P, Hu DL, Huang Y-F, Wang D, Zhou H-H. Effect of Schisandra chinensis ex- tract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica 2009; 39: 249-254 173
  23. Fan L, Tao G-Y, Wang G, Chen Y, Zhang W, He Y-J, Li Q, Lei H-P, Jiang F, Hu D-L, Huang Y-F, Zhou H-H. Effects of Ginkgo biloba extract inges- tion on the pharmcokinetics of talinolol in healthy Chinese volun- teers. Ann Pharmacother 2009; 43: 944-949 174
  24. Woelkart K, Feizlmayr E, Dittrich P, Beubler E, Pinl F, Suter A, Bauer R. Pharmacokinetics of bilobalide, ginkgolide A and B after administra- tion of three different Ginkgo biloba L. preparations in humans. Phytother Res 2010; 24: 445-450 183
  25. Kressmann S, Müller WE, Blume HH. Pharmaceutical quality of differ- ent Ginkgo biloba brands. J Pharm Pharmacol 2002; 54: 661-669 184
  26. Christensen LP. Ginsenosides: chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res 2008; 55: 1-99 191
  27. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degra- dation of ginsenosides on humans after oral administration. Drug Metab Dispos 2003; 31: 1065-1071 193
  28. Liu Y, Ma H, Zhang JW, Deng MC, Yang L. Influence of ginsenoside Rh1 and F1 on human cytochrome p 450 enzymes. Planta Med 2006; 72: 126-131 205
  29. Yuan C-S, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang- Lee M, Moss J. American ginseng reduces warfarinʼs effect in healthy patients: a randomized, controlled trial. Ann Intern Med 2004; 141: 23-27 222
  30. Jiang X, Blair EYL, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Phar- macol 2006; 46: 1370-1378 223
  31. Siddiqui BS, Gulzar T, Begum S, Afshan F, Sattar FA. Insecticidal amides from fruits of Piper nigrum Linn. Nat Prod Res 2005; 19: 143-150 265
  32. Selvendiran K, Thirunavukkarasu C, Singh JPV, Padmavathi R, Sakthi- sekaran D. Chemopreventative effect of piperine on mitochrondrial TCA cycle and phase-I and glutathione-metabolizing enzymes in benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice. Mol Cell Biochem 2005; 271: 101-106 285
  33. Xin H-W, Wu X-C, Li Q, Yu A-R, Xiong L. Effects of Schisandra sphenan- thera extract on the pharmacokinetics of midazolam in healthy vol- unteers. Br J Clin Pharmacol 2009; 67: 541-546 320
  34. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Böcker RH, Beckurts T, Lang W, Hunz M, Fuhr U. Inhibitory effects of silibin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000; 86: 250-256 335
  35. Beerhues L. Hyperforin. Phytochemistry 2006; 67: 2201-2207 369
  36. Nahrstedt A, Butterweck V. Lessons learned from herbal medicinal products: the example of St Johnʼs wort. J Nat Prod 2010; 73: 1015- 1021 370
  37. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyper- forin in St. Johnʼs wort interactions. Eur J Clin Pharmacol 2006; 62: 225-233 371
  38. Zhou S-F, Lai X. An update on clinical drug interactions with the herbal antidepressant St Johnʼs wort. Curr Drug Metab 2008; 9: 394-409 373
  39. Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dress- man J, Schubert-Zsilavecz M. Comparison of german St. Johnʼs wort products according to hyperforin and total hypericin content. J Am Pharm Assoc 2001; 41: 560-566 381
  40. Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Oha- shi K. The recovery time-course of CYP3A after induction by St Johnʼs wort administration. Br J Clin Pharmacol 2008; 65: 701-707 387
  41. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St Johnʼs Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604 391
  42. Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, Sievers H, Frank B, Riethling AK, Drewelow B. Effect of St Johnʼs wort dose and preparations on the pharmacokinetics of digox- in. Clin Pharmacol Ther 2004; 75: 546-557 393
  43. Wang LS, Zhu B, El-Aty AM, Zhou G, Li Z, Wu J, Chen GL, Jie L, Tang ZR, Wang A. The influence of St. Johnʼs wort on CYP2C19 activity with re- spect to genotype. J Clin Pharmacol 2004; 44: 577-581 394
  44. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I. Different effects of St Johnʼs wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70: 518-524 399
  45. Kawaguchi A, Ohmori M, Tsuruoka S-I, Nishiki K, Harada K, Miyamori I, Yano R-I, Nakamura T, Masada M, Fujimura A. Drug interaction be- tween St Johnʼs wort and quazepam. Br J Clin Pharmacol 2004; 58: 403-410 404
  46. de Maat MM, Hoetelmans RM, Math t RA, van Gorp EC, Meenhorst PL, Mulder JW, Beijnen JH. Drug interaction between St Johnʼs wort and nevirapine. AIDS 2001; 15: 420-421 405
  47. Schwarz U, Hanso H, Dresser G, Kim R, Fromm M, Oertel R, Miehlke S, Kirch W. St. Johnʼs wort reduces oral bioavailability of talinolol in healthy volunteers. Clin Pharmacol Ther 2002; 71: P33 406
  48. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. Johnʼs wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 1247-1249 408
  49. Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St Johnʼs wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol 2008; 153: 1579- 1586 414
  50. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug inter- action between St Johnʼs wort and cyclosporine. Ann Pharmacother 2000; 34: 1013-1016 415
  51. Hebert MF, Jeong MP, Yu-Luan C, Shahzad A, Anne ML. Effects of St. Johnʼs wort (Hypericum perforatum) on tacrolimus pharmaco- kinetics in healthy volunteers. J Clin Pharmacol 2004; 44: 89-94 419
  52. Eich-Hochli D, Oppliger R, Golay KP, Baumann P, Eap CB. Methadone maintenance treatment and St. Johnʼs wort -a case report. Pharma- copsychiatry 2003; 36: 35-37 421
  53. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, Li T, Liu J, Yang TL, Wang D. St Johnʼs wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004; 75: 191-197 422
  54. Lundahl A, Hedeland M, Bondesson U, Knutson L, Lennernas H. The effect of St. Johnʼs wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. Eur J Pharm Sci 2009; 36: 433-443

Cited by

Sorted by citations

See all 165

Related

See all

Metadata

Authors
Gurley, B., Fifer, E., & Gardner, Z.
Affiliations
  • University of Arkansas for Medical Sciences (US)
  • University of Massachusetts Amherst (US)
ORCID
Gurley, Bill
Venue
Planta Medica
Publisher
Georg Thieme Verlag KG
Published
2012-05-07
Volume
78
Issue
13
Pages
1490-1514
ISSN
  • 0032-0943 (ISSN-L)
  • 1439-0221
DOI
10.1055/s-0031-1298331
OpenAlex
W1983168442
Cited by
165
References
404
Citations by year
2026: 8 · 2025: 9 · 2024: 7 · 2023: 8 · 2022: 16 · 2021: 10 · 2020: 8 · 2019: 16 · 2018: 16 · 2017: 16 · 2016: 13 · 2015: 15 · 2014: 10 · 2013: 12 · 2012: 1
FWCI
2.80
Type
journal article
Language
en
Open access
Locations
  • Planta Medica (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Phytochemistry Medicinal Plant Applications
Keywords
herb-drug interactions, herbal supplements, cytochrome P450 inhibition, phytochemicals, orphan nuclear receptor, black cohosh, Echinacea, garlic, Ginkgo biloba, ginseng, goldenseal, kava, black pepper, piperine, Schisandra, Silybum marianum, Hypericum perforatum, methylenedioxyphenyl compounds
MeSH terms
Adenosine Triphosphate, Cytochrome P-450 Enzyme System, Humans, Pharmacokinetics, Transferases, Dietary Supplements, Magnoliopsida, Membrane Transport Proteins, Plant Preparations, Herb-Drug Interactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review